tradmap

CAI Earnings Caris Life Sciences, Inc.

Reported EPS, revenue and net income by fiscal period (SEC EDGAR) — quarterly and annual. Full financials → Chart & overview → Updated

Annual results

Diluted EPS (annual)
-$13 -$7 $0 2023 2024 2025
EPS
Revenue (annual)
$0 $406M $812M 2023 2024 2025
Revenue
Net income (annual)
-$341M -$171M $0 2023 2024 2025
Net income

Quarterly results

Diluted EPS (quarterly)
-$13 -$6 $0 Q2 '24 Q3 '24 Q1 '25 Q2 '25 Q3 '25 Q1 '26 Q2 '26
EPS
Revenue (quarterly)
$0 $146M $293M Q2 '24 Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26
Revenue
Net income (quarterly)
-$103M -$10M $82M $0 Q2 '24 Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26
Net income

Reported EPS history

1–10 of 10
Q2 20262026-06-300.002026-08-0510-Q
Q1 20262026-03-310.002026-05-0810-Q
FY 20252025-12-31-3.222026-03-0310-K
Q3 20252025-09-30-4.832025-11-0510-Q
Q2 20262025-06-30-12.802026-08-0510-Q
Q1 20262025-03-31-3.572026-05-0810-Q
FY 20252024-12-31-10.662026-03-0310-K
Q3 20252024-09-30-8.922025-11-0510-Q
Q2 20252024-06-30-6.342025-08-1210-Q
FY 20252023-12-31-13.242026-03-0310-K

Source: SEC EDGAR / XBRL (reported actuals; no consensus estimates). Some issuers (e.g. mortgage REITs, banks) don't report a conventional revenue line, so those charts may be omitted. Informational only — not financial advice.